Drug Database
CH

chloroprocaine hydrochloride (AMP 100 / AMP100 / Iheezo)

✓ Approved

Sintetica SA · 小分子 · 小分子

什么是 chloroprocaine hydrochloride?

chloroprocaine hydrochloride 是一种小分子,由Sintetica SA研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intraocular Injection、Topical。

药物档案

商品名AMP 100, AMP100, Iheezo
公司Sintetica SA
药物类别小分子
给药途径Injectable (Others), Intraocular Injection, Topical
状态Approved

治疗适应症

chloroprocaine hydrochloride 针对 3 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersAnaesthesia✓ Approved
Nervous system disordersSensory loss✓ Approved
Gastrointestinal disordersAbdominal pain✓ Approved

相关研究文献

PubMedFrontiers in aging2026-11-18

Effect of papaverine hydrochloride on functional visual acuity in non-arteritic central retinal artery occlusion: a retrospective cohort study.

Liu Zhongzhong Z, Lu Qingli Q, Liu Tong T, Peng Linna L et al.

Non-arteritic central retinal artery occlusion (NA-CRAO) is an acute ocular emergency that frequently results in severe and irreversible vision loss with limited therapeutic options. Papaverine hydrochloride, a non-specific vasodilator commonly used to relieve vasospasm, has not been previously evaluated for its potential benefits for visual recovery in patients with NA-CRAO. Therefore, this study aims to investigate the association between papaverine hydrochloride treatment (PHt) and functional visual acuity improvement in patients with NA-CRAO. Propensity-score matching was used to retrospectively collect clinical data of 104 NA-CRAO patients with similar baseline characteristics. The patients were categorized into a PHt group (n = 52) and a non-papaverine hydrochloride treatment (non-PHt) group (n = 52). The primary outcome was functional visual acuity (best-corrected visual acuity ≥20/100) assessed at discharge and at a 1-month follow-up. Logistic regression and subgroup analyses were performed to evaluate the associations between papaverine hydrochloride use and improvements in functional visual acuity. The PHt group showed significantly higher functional visual acuity than the non-PHt group at discharge (32.7% vs. 15.4%, p = 0.039) and at the 1-month follow-up (53.8% vs. 34.6%, p = 0.048). In adjusted models, treatment with papaverine hydrochloride was an independent favorable factor for improved functional visual acuity at discharge (odds ratio [OR] = 3.52, 95% confidence interval [CI]: 1.20-10.36, p = 0.022) and at the 1-month follow-up (OR = 3.15, 95% CI: 1.19-8.29, p = 0.020). Subgroup analyses demonstrated consistent therapeutic effects across age, sex, the side of the affected eye, intra-arterial thrombolysis and intravenous thrombolysis strata, with no statistically significant interaction effects identified at either time point (all Pinteraction >0.05). Treatment with papaverine hydrochloride was significantly associated with visual recovery in patients with NA-CRAO. Prospective further studies of causality are needed to validate these results and assess their safety.

PMID 43047374
阅读全文 →
PubMedDermatitis : contact, atopic, occupational, drug2026-11-18

Periorbital Allergic Contact Dermatitis to Sodium Metabisulfite in Prednisolone Acetate Ophthalmic Suspension.

Thiraviyarajah Vaish V, Khouri Ashley A, Schlarbaum Jamie P JP

PMID 43046635
阅读全文 →
PubMedJournal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society2026-11-18

Should Routine PCJ Prophylaxis Be Used for Neuro-ophthalmic Patients Receiving Chronic Prednisone?

Carey Andrew R AR, Mackay Devin D DD, McClelland Collin M CM, Van Stavern Gregory P GP

PMID 43049203
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Ophthalmic Vascular Occlusion and Blindness After Platelet-Rich Plasma Injections: A Systematic Review.

Ebrahimzade Mandana M, Nazari Shahriar S, Pourani Mohammad Reza MR, Muñoz-Gonzalez Cristina C et al.

Platelet-rich plasma (PRP) is widely used in aesthetic and regenerative medicine; however, rare vision-threatening complications such as blindness have been reported following facial injections. This systematic review aimed to identify and analyze all published cases of visual impairment following PRP injections. A systematic literature search was performed until August 2025, using PubMed, Embase, and Scopus, supplemented by a manual Google Scholar search. Search terms combined "platelet-rich plasma" with ophthalmic complications. Case reports describing visual impairment after PRP injection were included without date or language restrictions. Data extracted included patient demographics, indication, injection site, onset and pattern of vision loss, ophthalmologic findings, management, and outcome. Seven articles reporting 10 cases of PRP-associated unilateral visual loss published between 2017 and 2025 were identified. All patients were female (22-64 years). Most cases (n = 9) followed PRP injections for facial rejuvenation, predominantly in the glabella (n = 6) and forehead (n = 4), while one followed scalp PRP for alopecia. Vision loss was immediate and painful in 9 cases; 8 presented with no light perception. Two cases with delayed or partial visual impairment demonstrated visual recovery after corticosteroid therapy. Fundoscopic findings indicated retinal and choroidal ischemia. Although rare, PRP injections can cause irreversible blindness, likely due to embolic ophthalmic artery occlusion (OAO). Prevention through safe injection technique is essential, as treatment options remain limited and often ineffective. Over half of the reported cases were performed by non-physicians or inadequately trained practitioners, underscoring the critical need for proper credentials and training.

PMID 43047023
阅读全文 →
PubMedJournal of the science of food and agriculture2026-11-18

Development and characterization of l-cysteine incorporated gelatin-carboxymethylcellulose hydrogel for extending the shelf life of button mushrooms.

Abdolshah Zahra Z, Bolandi Marzieh M, Abdolshahi Anna A

This study investigated gelatin-carboxymethyl cellulose (GEL-CMC) hydrogels containing l-cysteine (l-Cys) as edible coating systems for maintaining the postharvest quality of button mushrooms (Agaricus bisporus) during refrigerated storage. Four l-Cys concentrations (2, 3, 4 and 5 g L-1) were incorporated into GEL-CMC hydrogels, with a GEL-CMC formulation without l-Cys serving as the control. Incorporation of l-Cys modified the physicochemical, functional, mechanical, barrier and thermal properties of the hydrogels and hydrogel films in a concentration-dependent manner. Fourier transform infrared and X-ray diffraction analyses indicated changes in the molecular environment and structural organization of the GEL-CMC matrix following l-Cys incorporation, whereas scanning electroni microscopy observations revealed concentration-dependent changes in film morphology. The l-Cys-containing formulations also exhibited differences in DPPH (i.e. 2,2-diphenyl-1-picrylhydrazyl) radical-scavenging activity and total flavonoid content. During refrigerated storage, mushrooms coated with l-Cys-containing formulations generally showed improved retention of quality attributes, including reduced weight loss and browning, better firmness retention, lower malondialdehyde accumulation and lower microbial counts, although the magnitude of the effects varied among quality parameters and l-Cys concentrations. GEL-CMC/l-Cys hydrogel coatings showed promising potential for postharvest preservation of button mushrooms under refrigerated storage conditions. Incorporation of l-Cys provided an approach for modifying the performance of the GEL-CMC coating matrix and improving the retention of selected mushroom quality attributes during storage. These findings support the potential of GEL-CMC/l-Cys hydrogels as edible coating systems for postharvest applications and provide a basis for further optimization of their formulation and application conditions. © 2026 Society of Chemical Industry.

PMID 43046113
阅读全文 →
PubMedJournal of nanobiotechnology2026-11-18

A dual-crosslinked herbal hydrogel for multimodal therapy of ulcerative colitis via IL-34/IL-22 modulation.

Chen Xinxin X, Sun Jiang J, Yang Ruiwen R, Sun Chengtao C et al.

Ulcerative colitis (UC) represents a prevalent idiopathic inflammatory disease characterized by impaired mucosal repair, gut microbiotal dysbiosis and compromised immune function. Conventional therapeutic approaches predominantly focus on symptom management, frequently resulting in the excessive use of pharmaceuticals. Herein, we report a dual-crosslinked gel system (GE-GA@GP gel, abbreviated as GG gel) composed of Gardenia jasminoides E llis polysaccharide (GP) and glycyrrhizic acid (GA) loaded with geniposide (GE) to simultaneously target barrier dysfunction and immune dysregulation. Derived from natural sources, these functional ingredients form hydrogel structures through spontaneous molecular self-assembly, ensuring excellent biocompatibility. Specifically, the GP imparts pH-responsive properties to the GG gel, thus enhancing therapeutic efficacy. Additionally, GA increases epithelial membrane fluidity, promoting the transmembrane transport of GE and enhancing drug penetration into the inflamed tissues. In vivo evaluations demonstrate that the GG gel exerts its therapeutic effect by restoring damaged mucosal tissues, modulating intestinal mucosal immune responses, and rebalancing gut microbial homeostasis. Mechanistic investigations demonstrate that the GG gel enables effective intervention against UC by activating IL-22 expression to mediate intestinal mucosal repair, suppressing IL-34 expression to attenuate intestinal inflammatory infiltration, and promoting macrophage polarization to exert synergistic therapeutic effects. Collectively, this study presents a comprehensive multimodal therapeutic approach that integrates the restoration of the physical barrier, regulation of gut microbiota, and robust modulation of deep-seated immune dysregulation, thereby offering an effective strategy for the treatment of UC.

PMID 43046119
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多chloroprocaine hydrochloride